Gyre Therapeutics, Inc. License and Services Revenue (Deprecated 2018-01-31)
Gyre Therapeutics, Inc. (GYRE) reported License and Services Revenue (Deprecated 2018-01-31) of $3.54 million for the 12-month period ending 2013-12-31, per its 10-K filed 2015-03-16.
Discontinued › Income Statement › Other Income
us-gaap:LicenseAndServicesRevenue · last filed 2015-03-16
- Gyre Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2013-09-30 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2013-06-30 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2013-03-31 was $3.54M, a 84.36% decline year-over-year.
- Gyre Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for fiscal 2013 was $3.54M, a 93.84% decline from fiscal 2012.
- Gyre Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for fiscal 2012 was $57.42M, a 40.79% decline from fiscal 2011.
- Gyre Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for fiscal 2011 was $96.98M, a 16.31% increase from fiscal 2010.
- Gyre Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for fiscal 2010 was $83.38M, a 340.37% increase from fiscal 2009.
| Period end | License and Services Revenue (Deprecated 2018-01-31) 3 month | License and Services Revenue (Deprecated 2018-01-31) 6 month | License and Services Revenue (Deprecated 2018-01-31) 9 month | License and Services Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $0.00 derived: sum of 2 quarters · filed 2015-03-16 | $0.00 derived: sum of 3 quarters · filed 2015-03-16 | $3.54M 10-K · filed 2015-03-16 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 derived: sum of 2 quarters · filed 2014-11-06 | $3.54M 10-Q · filed 2014-11-06 | $4.13M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $3.54M 10-Q · filed 2014-08-07 | $4.13M derived: sum of 3 quarters · filed 2015-03-16 | $4.86M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-03-31 | $3.54M 10-Q · filed 2014-05-08 | $4.13M derived: sum of 2 quarters · filed 2015-03-16 | $4.86M derived: sum of 3 quarters · filed 2015-03-16 | $38.35M derived: sum of 4 quarters · filed 2015-03-16 |
| 2012-12-31 | $590.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $1.33M derived: sum of 2 quarters · filed 2015-03-16 | $34.81M derived: sum of 3 quarters · filed 2015-03-16 | $57.42M 10-K · filed 2015-03-16 |
| 2012-09-30 | $736.00K 10-Q · filed 2013-11-06 | $34.22M derived: sum of 2 quarters · filed 2013-11-06 | $56.83M 10-Q · filed 2013-11-06 | $75.65M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-06-30 | $33.49M 10-Q · filed 2013-08-07 | $56.09M 10-Q · filed 2013-08-07 | $74.91M derived: sum of 3 quarters · filed 2014-03-14 | $93.45M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-03-31 | $22.61M 10-Q · filed 2013-05-08 | $41.43M derived: sum of 2 quarters · filed 2014-03-14 | $59.97M derived: sum of 3 quarters · filed 2014-03-14 | $80.66M derived: sum of 4 quarters · filed 2014-03-14 |
| 2011-12-31 | $18.82M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $37.36M derived: sum of 2 quarters · filed 2014-03-14 | $58.06M derived: sum of 3 quarters · filed 2014-03-14 | $96.98M 10-K · filed 2014-03-14 |
| 2011-09-30 | $18.54M 10-Q · filed 2012-11-08 | $39.24M derived: sum of 2 quarters · filed 2012-11-08 | $78.16M 10-Q · filed 2012-11-08 | $100.08M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-06-30 | $20.70M 10-Q · filed 2012-08-09 | $59.62M 10-Q · filed 2012-08-09 | $81.55M derived: sum of 3 quarters · filed 2013-03-15 | $103.21M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-03-31 | $38.92M 10-Q · filed 2012-05-09 | $60.85M derived: sum of 2 quarters · filed 2013-03-15 | $82.51M derived: sum of 3 quarters · filed 2013-03-15 | $103.21M derived: sum of 4 quarters · filed 2013-03-15 |
| 2010-12-31 | $21.93M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $43.59M derived: sum of 2 quarters · filed 2013-03-15 | $64.29M derived: sum of 3 quarters · filed 2013-03-15 | $83.38M 10-K · filed 2013-03-15 |
| 2010-09-30 | $21.66M 10-Q · filed 2011-11-03 | $42.37M derived: sum of 2 quarters · filed 2011-11-03 | $61.45M 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $20.70M 10-Q · filed 2011-08-09 | $39.79M 10-Q · filed 2011-08-09 | ||
| 2009-12-31 | $18.93M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |